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OBJECTIVE—Lipoic acid synthase (LASY) is the enzyme that is
involved in the endogenous synthesis of lipoic acid, a potent
mitochondrial antioxidant. The aim of this study was to study the
role of LASY in type 2 diabetes.
RESEARCH DESIGN AND METHODS—We studied expres-
sion of LASY in animal models of type 2 diabetes. We also looked
at regulation of LASY in vitro under conditions that exist in
diabetes. Additionally, we looked at effects of LASY knockdown
on cellular antioxidant status, inﬂammation, mitochondrial func-
tion, and insulin-stimulated glucose uptake.
RESULTS—LASY expression is signiﬁcantly reduced in tissues
from animal models of diabetes and obesity compared with age-
and sex-matched controls. In vitro, LASY mRNA levels were
decreased by the proinﬂammatory cytokine tumor necrosis fac-
tor (TNF)- and high glucose. Downregulation of the LASY gene
by RNA interference (RNAi) reduced endogenous levels of lipoic
acid, and the activities of critical components of the antioxidant
defense network, increasing oxidative stress. Treatment with
exogenous lipoic acid compensated for some of these defects.
RNAi-mediated downregulation of LASY induced a signiﬁcant
loss of mitochondrial membrane potential and decreased insulin-
stimulated glucose uptake in skeletal muscle cells. In endothelial
cells, downregulation of LASY aggravated the inﬂammatory
response that manifested as an increase in both basal and
TNF-–induced expression of the proinﬂammatory cytokine,
monocyte chemoattractant protein-1 (MCP-1). Overexpression of
the LASY gene ameliorated the inﬂammatory response.
CONCLUSIONS—Deﬁciency of LASY results in an overall dis-
turbance in the antioxidant defense network, leading to in-
creased inﬂammation, insulin resistance, and mitochondrial
dysfunction. Diabetes 58:600–608, 2009
T
ype 2 diabetes is the most prevalent chronic
metabolic disease in the world. In the past
decade, considerable evidence has accumulated
implicating oxidative stress as a key factor that
accelerates the onset and progression of type 2 diabetes.
Chronic oxidative stress causes inﬂammation and mito-
chondrial dysfunction and culminates in insulin resis-
tance, which ultimately progresses to diabetes. Oxidative
stress also promotes cellular dysfunction and damage,
leading to the development of secondary complications of
diabetes. The underlying cause of redox imbalance is a
deﬁciency in the endogenous antioxidant network. This
deﬁciency would result in an inability to combat excessive
amounts of reactive oxygen species (ROS) and tip the
balance in favor of oxidative stress.
Redox balance is maintained by an antioxidant defense
network within mitochondria, consisting of stress-responsive
enzymes such as superoxide dismutase (SOD), catalase and
reduced glutathione (GSH), and antioxidants. The antioxi-
dant defense network is activated in response to excessive
production of ROS in the mitochondria, thereby neutralizing
the ROS before they inﬂict damage on cellular molecules.
Lipoic acid is a potent mitochondrial antioxidant that plays a
central role in establishing and maintaining the antioxidant
defense network by effectively scavenging ROS and regener-
ating critical antioxidants (1). Lipoic acid is also an essential
cofactor of mitochondrial enzyme complexes involved in
oxidative metabolism. Exogenous lipoic acid, by virtue of its
antioxidant effect, has been shown to be beneﬁcial in many
metabolic and vascular diseases (2–7). Endogenously, lipoic
acid is synthesized from octanoic acid by the action of LASY.
Previously, synthesis of lipoic acid was believed to be an
exclusively prokaryotic phenomenon, and existence of LASY
in higher organisms was unknown. The discovery that mam-
malian cells are capable of synthesizing lipoic acid was made
quite recently, when a mouse homolog of LASY was identi-
ﬁed (8). Mammalian LASY contains a putative mitochondria
targeting sequence at the NH2-terminus and is mainly local-
ized in mitochondria (8). Thus, LASY is ideally positioned to
generate lipoic acid at the site of action, namely, mitochon-
dria. Although the pharmacological effects of lipoic acid have
been explored in many studies, the importance of endoge-
nous lipoic acid is largely unknown. In this study, we
explored the role of LASY in diabetes and inﬂammation. Our
data show for the ﬁrst time that LASY is downregulated in
diabetes and inﬂammation. Downregulation of LASY resulted
in decreased endogenous lipoic acid levels. The data that we
have presented suggest that downregulation of LASY, and the
resultant decrease in endogenous lipoic acid, would cause
redox imbalance leading to inﬂammation and mitochondrial
dysfunction, two important hallmarks of diabetes.
RESEARCH DESIGN AND METHODS
Reagents. Unless otherwise stated, reagents were purchased from Sigma-
Aldrich (St. Louis, MO).
Rodents, diets, and housing. Rodents for in vivo studies were purchased
from Jackson or Charles River Laboratories. Animals were housed in groups
of two to four upon arrival. All animals were allowed to feed ad libitum on a
regular diet (Laboratory Rodent Diet, 5001, LabDiet, Inc.). Characteristics of
the animals used in the study are outlined in the Supplementary Table, found
in an online-only appendix at http://dx.doi.org/10.2337/db08-0473.
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orbital bleed. Skeletal muscle (soleus), adipose tissue (visceral fat pad), and
liver sections were collected after euthanization of the animals.
Cell growth and differentiation. Human skeletal muscle myoblasts
(HSMMs) (Cambrex) were grown and differentiated according to Cambrex’s
protocol. Human microvascular endothelial cells (HMVECs) and human aortic
endothelial cells (Cambrex) were grown in HMVEC-MV/HMVEC growth media
(Cambrex) until 80% conﬂuent for treatments or transfections.
Real-time PCR. LASY real-time quantitative PCR was performed using LASY
primers and the Brilliant SYBR Green one-step RT-PCR kit (Stratagene).
Oligonucleotide primers for human LASY were designed using real-time PCR
primer design software and were custom-made (Supplementary Methods).
For GAPDH and Actin real-time PCR, validated primer sets were purchased
from SuperArray.
Ampliﬁcations were performed using the Mx3000P instrument (Stratagene)
according to the manufacturer’s instructions. Values obtained for the genes of
interest (LASY, GAPDH) were normalized to values for a housekeeping gene,
Actin.
Knockdown studies. Knockdown of the LASY gene was achieved by RNA
interference (RNAi).
The siRNA duplex for LASY knockdown was custom-designed and synthe-
sized by Dharmacon. The negative control for the siRNA LASY knockdown
experiment consisted of a nontarget (control siRNA) oligo (Dharmacon). Differ-
entiated cells were treated with siRNA oligos (10 nmol/l) and TransIT-KO reagent
(Mirius) for 24–48 h at 37°C/CO2.
Overexpression studies. The human LASY gene was ampliﬁed from human
aortic endothelial cells by Oligo dT priming with the Superscript ﬁrst-strand
synthesis system (Invitrogen). The ampliﬁcation product was cloned into the
pBKCMV vector. Presence of insert in the correct orientation was veriﬁed by
PCR and sequencing.
Transfections. Transfections were done using Targefect reagents (Targeting
Systems) using the manufacturer’s protocol. Transfections were done in
100-mm plates for all assays. Transfections were allowed to proceed for 24 h,
after which the cells were replated into 96- or 24-well plates and incubated for
18 h before treatments.
Glucose uptake assay. The glucose uptake assay in HSMMs was performed
by adapting the protocol described by Maddux et al. (9), with modiﬁcations as
described in the ﬁgure legends.
Cell treatments. For HSMMs, treatments with compounds or cytokines and
growth factors were done on differentiated cells. Cell treatments were done as
described in the ﬁgure legends.
RNA isolation. RNA was isolated from cultured cells using the Absolutely RNA
96 microprep kit (Stratagene) following the manufacturer’s protocol. RNA from
tissue samples was isolated using tissue-speciﬁc kits from Qiagen.
Monocyte chemoattractant protein-1 enzyme-linked immunosorbent
assay. Monocyte chemoattractant protein-1 (MCP-1) enzyme-linked immu-
nosorbent assay (ELISA) was carried out using the Quantikine Human MCP-1
kit as described by the manufacturer (R&D Systems).
Western blot analysis and antibodies. Western blot was done as described
in the ﬁgure legends. Monoclonal mouse anti-LASY antibodies were purchased
from Novus Biologicals. Polyclonal anti-rabbit lipoic acid antibodies were
purchased from Calbiochem. Monoclonal mouse antibodies speciﬁc for PDH
(E2/E3 subunits) were purchased from Molecular Probes. Puriﬁed pyruvate
dehydrogenase complex (PDC) (E2 subunit) (bovine heart) was purchased
from Globozymes. Secondary, horseradish peroxidase–conjugated IgG (HL)
antibodies were purchased from Zymed labs.
Detection of mitochondrial membrane potential. Changes in mitochon-
drial membrane potential were determined using a JC-1 assay kit (Biotium) as
described by the manufacturer.
Glutathione assay. To determine intracellular levels of reduced glutathione
(GSH), cells were lysed with protein lysis buffer 48 h after initiation of LASY
knockdown. GSH levels were determined using the Glutathione assay kit
(Biochain) following the manufacturer’s instructions. Data were expressed
per milligram protein determined by the MicroBCA technique.
Catalase assay. Catalase (CAT) activity was determined using a CAT assay
kit purchased from Cayman Chemical.
SOD assay. SOD activity was determined by using a SOD assay kit from
Cayman Chemical. The assay was used to measure total SOD (Cu/Zn-, Mn-,
and Fe-SOD) as well as cytosolic and mitochondrial SOD activities in the
samples. Cells were grown in six-well plates for the SOD assay and analyzed
for SOD activity 48 h after initiation of LASY knockdown.
Superoxide assay. Production of superoxide anion was measured with a
commercially available kit (Sigma-Aldrich). The kit uses a chemiluminescent
method to measure the oxidation of luminol by superoxide anions.
RESULTS
The LASY gene is downregulated in animal models of
diabetes and obesity. To understand the role of LASY in
diabetes, we ﬁrst determined LASY expression in a mouse
model of type 2 diabetes (db/db). Skeletal muscle and
adipose tissue are key players that contribute to insulin
resistance in type 2 diabetes. LASY gene expression is
signiﬁcantly downregulated in both skeletal muscle (P 
0.02) and adipose tissue (P  0.004) of db/db mice com-
pared with their normoglycemic heterozygous (db/)
counterparts and normal control mice (Fig. 1A). Interest-
ingly, there was no decrease in LASY mRNA levels in the
liver of db/db mice compared with the db/ or nondiabetic
mice. There was a small increase that was insigniﬁcant.
Downregulation of LASY in adipose tissue of db/db mice
translated to a signiﬁcant decrease in endogenous lipoic
acid levels (Fig. 1C). The anti–lipoic acid antibodies used
in the blot detected lipoic acid bound to the E2 subunits of
PDC and -ketoglutarate dehydrogenase (KDH), two key
mitochondrial enzymes that use lipoic acid as a cofactor
(P  0.007, P  0.005, for lipoic acid–PDC-E2 and lipoic
acid–KDH-E2, respectively) compared with db/ mice
(Fig. 1C). This suggests that in diabetic mice such as db/db,
decrease in LASY results in a decrease in endogenous
lipoic acid levels. We also studied LASY mRNA levels in
adipose tissue from two other animal models of obesity,
the ob/ob mouse model and Zucker fa/fa rat model. As seen
in the case of the db/db mice, LASY expression was
signiﬁcantly reduced in these obese models compared
with their lean counterparts (Fig. 1B, ob/ob, P  0.0001,
Zucker fa/fa, P  0.03).
LASY expression in vitro is downregulated by condi-
tions that exist in diabetes. Hyperglycemia and in-
creased secretion of inﬂammatory cytokines are two
hallmarks of diabetes. To understand the regulation of
LASY, HMVECs were subjected to treatment with medium
containing TNF- or high glucose (Fig. 2). Treatment with
glucose (25 mmol/l) led to a signiﬁcant downregulation
(P  0.02) in LASY mRNA levels in endothelial cells.
Intermediary levels of glucose (11 mmol/l) or an osmotic
control (D-mannitol) did not signiﬁcantly affect LASY ex-
pression (Supplementary Fig. 1, found in the online appen-
dix). Treatment of HSMMs with 25 mmol/l glucose also
reduced LASY mRNA levels signiﬁcantly (Fig. 2, P  0.02).
Treatment of both endothelial cells and skeletal muscle
cells with TNF- signiﬁcantly decreased LASY mRNA
levels (Fig. 2, P  0.001). Thus, consistent with the animal
data, which suggests reduction in LASY in diabetes, LASY
appears to be susceptible to downregulation by hypergly-
cemia and inﬂammatory cytokines.
Inhibition of LASY expression decreases mitochon-
drial lipoic acid levels. We knocked down the LASY
gene in HSMMs using the siRNA-based gene silencing
approach. Using this approach, we were able to get 51%
knockdown of the LASY gene after 48 h (Fig. 3A). As
shown in Fig. 3B, the knockdown was speciﬁc to LASY,
since expression of a housekeeping gene such as
GAPDH was not affected. Consistent with the real-time
PCR data, knockdown of LASY resulted in a signiﬁcant
reduction in LASY protein levels (Fig. 3C, P  0.009).
We then studied the effect of LASY knockdown on
endogenous lipoic acid levels by using Western blot
analysis. As shown in Fig. 3D, knockdown of LASY
resulted in a signiﬁcant decrease in lipoic acid that is
associated with PDC and KDH (P  0.01). However,
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protein (Fig. 3E). Thus, knockdown of LASY directly
translates to a decrease in lipoic acid associated with
the E2 subunit of PDC, without affecting levels of E2
protein. These results are consistent with our in vivo
results in which downregulation of LASY in tissues
translated to a decrease in lipoic acid levels (Fig. 1C).
Knockdown of LASY decreases intracellular GSH
levels in human skeletal muscle cells. The antioxidant
properties of lipoic acid facilitate the regeneration of other
antioxidants such as reduced GSH, which in turn protects
cells from oxidative damage (1). We hypothesized that
reduction in the levels of lipoic acid due to LASY knock-
down would result in a decrease in intracellular GSH
levels. We studied the GSH levels in HSMMs in response to
LASY knockdown. Compared with the control siRNA
oligo, there was a signiﬁcant decrease (P  0.005) in GSH
levels in cells treated with LASY siRNA (Fig. 4A).
Knockdown of LASY results in decreased activities of
superoxide dismutase and catalase and increased
superoxide anion levels. To further investigate the effect
of LASY knockdown on the cellular antioxidant defense
network, we determined the activities of two critical
antioxidant enzymes, CAT and SOD, in HSMMs after
knockdown of LASY. As shown in Fig. 4, knockdown of
LASY results in a signiﬁcant decrease in the activities of
catalase (Fig. 4B) and mitochondrial and cytosolic SOD
(Fig. 4C and D). Treatment with 500 mol/l lipoic acid
restored the activities of these enzymes (Fig. 4B–D). There
was a concentration-dependent effect between 100 and
500 mol/l of lipoic acid. Based on the decrease in SOD
activity, we hypothesized that there would be an increase
in superoxide anion levels with LASY knockdown. This
turned out to be true, since there was a signiﬁcant increase
in superoxide anion levels both in basal and TNF-–
treated conditions (Fig. 4E). Treatment with lipoic acid
(500 mol/l) did not decrease the superoxide anion levels.
Instead, there was a signiﬁcant increase in superoxide
anion levels with lipoic acid treatment in both control and
LASY siRNA-treated samples, compared with the TNF-–
treated levels. The difference between control and LASY
siRNA-treated samples was also signiﬁcant, suggesting
that lipoic acid treatment worsens the TNF-–induced
accumulation of superoxide when LASY is deﬁcient.
Reduced LASY expression results in decreased glu-
cose uptake in skeletal muscle cells. One of the factors
contributing to hyperglycemia is insulin resistance, which
causes reduced glucose uptake by skeletal muscle. Based on
our observation that LASY expression is downregulated in
the skeletal muscle of insulin-resistant animals, we studied
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FIG. 1. LASY mRNA and lipoic acid (LA) levels in obese diabetic animal
models compared with normal controls. A: LASY mRNA levels in skeletal
muscle, adipose, and liver tissues from db/db mice. B: LASY mRNA levels
in adipose tissue of ob/ob mice and Zucker fa/fa rats. n  3 in each group.
Ct values obtained from LASY primers were corrected for Ct values from
Actin primers. Fold changes were calculated and expressed as a percent of
the fold change of control(s). P values were calculated using Student’s t
test (one-tailed, unpaired). A: For db/db versus db/,* P < 0.02 for
skeletal muscle (SkM), *P < 0.004 for adipose tissue. B: For ob/ob versus
C57, ***P < 0.0001. For fa/fa versus lean, **P < 0.03. C: Endogenous
lipoic acid levels in adipose tissue (visceral fat pads) of db/db mice
compared with db/ mice. n  3 in each group. Western blot (top panel):
Upper and lower bands represent LA-PDC-E2 and LA-KDH-E2, respec-
tively. Middle panel shows Actin. Quantitation of the WB for LA-PDC-E2
and LA-KDH-E2 is shown in the bottom panel. Results are means  SD. P
values were calculated using the Student’s t test (one-tailed, unpaired).
*P < 0.007 and P < 0.005 for db/db versus db/ for LA-PDC and LA-KDH,
respectively.
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FIG. 2. LASY mRNA levels in human endothelial and skeletal muscle
cells after treatment with pro-inﬂammatory agents. HMVECs and
HSMMs were used in the experiment. Concentrations of TNF- used
for stimulation of the two cell types were based on the MCP-1
responses; HSMMs required a higher concentration of TNF- to secrete
detectable amounts of MCP-1. HMVECs were treated with 0.05 ng/ml of
TNF-; HSMMs were treated with 1 ng/ml of TNF-. Glucose concen-
tration for both cell types: 25 mmol/l. Controls and treatments were
done for 18 h in low-serum (1% fetal bovine serum) media. Fold
changes were calculated and expressed as percent of untreated control
cells. **P < 0.001, *P < 0.02. Results represent means  SE of three
independent experiments. P values were calculated using Student’s t
test (one-tailed, unpaired). o, Untreated control; f, TNF; , glucose.
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skeletal muscle cells. We knocked down the LASY gene by
siRNA-based gene silencing and studied the effect of the
knockdown on [
3H]-2-deoxy glucose uptake in skeletal mus-
cle cells. As in our earlier experiments, we obtained a
substantial knockdown (64%) with the LASY siRNA oligo
compared with the control siRNA oligo in HSMM cells (data
not shown). Decreased LASY expression in skeletal muscle
cells signiﬁcantly reduced insulin-stimulated glucose uptake
(Fig. 5A)( P  0.01). There was a small, insigniﬁcant
decrease in basal glucose uptake (Fig. 5A). These data
demonstrate that downregulation of LASY has a contrib-
utory role on insulin resistance in skeletal muscle.
Reduced LASY expression decreases mitochondrial
membrane potential in human skeletal muscle cells.
Because a decline in mitochondrial function is one of the
causes of insulin resistance in diabetes, we tested if a
decrease in LASY would affect mitochondrial function. We
studied the effect of siRNA-based knockdown of LASY on
mitochondrial membrane potential. Mitochondrial mem-
brane potential was measured in terms of the ratio of red
to green ﬂuorescence of a cationic dye, JC-1 (see RESEARCH
DESIGN AND METHODS). Reduced LASY expression was ac-
companied by a signiﬁcant decrease (P  0.003) in the
ratio of red to green ﬂuorescence of JC-1 dye, indicating
that LASY knockdown affects mitochondrial membrane
potential (Fig. 5B).
Inhibition of LASY exacerbates inﬂammation. In-
crease in inﬂammation and consequent endothelial cell
dysfunction, which are two other hallmarks of diabetes,
play a contributory role in atherosclerosis. We tested if
knocking down the LASY gene would affect the inﬂamma-
tory response in endothelial cells. Using the RNAi ap-
proach, we were able to get 88% knockdown of LASY in
HMVECs (Fig. 6A, P  0.001). Concomitant with LASY
reduction, basal secretion of MCP-1 in HMVECs with
reduced expression of LASY was signiﬁcantly increased
(Fig. 6B, P  0.05). Treatment with TNF- further elevated
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FIG. 3. Effect of siRNA-based LASY knockdown on LASY expression and endogenous lipoic acid (LA) levels in HSMMs. A: LASY mRNA levels in
HSMMs treated with a LASY siRNA oligo or control (scrambled) siRNA oligo. B: GAPDH mRNA levels in HSMMs treated with LASY siRNA oligo
or control (scrambled) siRNA oligo. Ct values from real-time PCR assays for LASY and GAPDH were corrected for Ct values from Actin. Fold
changes were calculated as percent of fold change of control. C: Western blot analysis of cell lysates from HSMMs treated with LASY siRNA oligo
(L) or scrambled control oligo (C) using monoclonal anti-mouse antibodies directed to a peptide epitope of recombinant LASY protein (Novus
Biologicals). Cells were grown in 24-well plates. After gene knockdown, cells were lysed with protein lysis buffer (0.5% SDS, 50 mmol/l Tris-HCl,
pH 8.0, 1 protease inhibitor cocktail, Sigma). Protein concentration was determined using the MicroBCA kit (Pierce). Equivalent amounts of
protein were analyzed by SDS-PAGE (NuPage precast gels). Western blotting protocols were done as described by the antibody manufacturer.
Bands were quantitated by densitometry, using the Total Lab software. A 1:500 dilution of the antibody detected an 55-kDa band (upper panel).
Actin is shown in the middle panel. Quantitation of the blot is shown in the lower panel. Results represent means  SE of three independent
experiments. P values were calculated using the Student’s t test (one-tailed, unpaired). *P < 0.009 for LASY siRNA versus Control siRNA. D:
Western blot analysis of cell lysates from HSMMs treated with LASY siRNA oligos (L) or scrambled control oligo (C) using polyclonal anti–lipoic
acid (LA) rabbit antibodies directed to E2 subunit of PDC or KDH (above) or Actin antibodies (below). Puriﬁed PDC(E2 subunit) from bovine
heart (GloboZymes) was run on the gel alongside cell lysates. The two bands in lipoic acid Western blot represent lipoic acid bound to E2 subunit
of PDC (upper band, LA-PDC-E2) or -KGD (lower band, LA-KDH-E2). Quantitation of LA-PDC-E2 and LA-KDH-E2 bands in control and LASY
siRNA lanes is shown to the right; values are normalized to Actin values. Results are means  SE of three independent experiments. P values were
calculated using the Student’s t test (one-tailed, unpaired). *P < 0.01, LASY siRNA versus control siRNA for LA-PDC-E2 and LA-KDH-E2. E:
Western blot analysis of cell lysates from HSMMs treated with monoclonal antibodies speciﬁc for pyruvate dehydrogenase (E2/E3 components
of PDC) (Molecular Probes). The top band represents E2 subunit of PDC. Puriﬁed PDC (E2 subunit) was run on the gel alongside cell lysates.
Quantitation of E2 band is shown to the right. Values were normalized to values for Actin (bottom panel).
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FIG. 4. Effect of LASY knockdown on the antioxidant system in HSMMs. A: Effect of LASY knockdown on intracellular reduced glutathione
levels. Intracellular GSH levels in HSMMs treated with LASY or control siRNA oligos was quantitated using the GSH assay as described in
the text. Results for GSH are corrected for amount of protein. Data represent the means  SD of three independent experiments. P values
were calculated using Student’s t test (one-tailed, unpaired). *P < 0.003 for LASY siRNA versus control siRNA. B–D: Effect of siRNA-based
LASY knockdown on activities of catalase (B), mitochondrial superoxide dismutase (Mn-SOD) (C), and cytosolic SOD (Cu-Zn-SOD) (D).
Knockdown was done as described in the text. Treatments with lipoic acid were done as described in the earlier section, 24 h after
knockdown. B: Effect of LASY knockdown on catalase activity in HSMMs. One unit is deﬁned as the amount of enzyme that will cause the
formation of 1.0 nmol formaldehyde per minute at 25°C. Catalase activity was determined using a kit from Cayman Chemical. The standard
curve was generated using a formaldehyde standard. Data represent means  SD of three independent experiments. Catalase enzyme
activity was determined in duplicate. Signiﬁcance was calculated using Student’s t test (one-tailed, unpaired). P < 0.01 for LASY siRNA
versus control siRNA; P < 0.006 for LASY siRNALA100 versus LASY siRNA; P < 0.008 for LASY siRNALA500 versus LASY siRNA. C and
D: Effect of LASY knockdown on SOD activity in HSMMs. One unit is deﬁned as the amount of enzyme needed to exhibit 50% dismutation
of the superoxide radical. SOD activity was determined using a kit from Cayman Chemical. To separate cytosolic (Cu/Zn) and mitochondrial
(Mn) SOD, cell lysate supernatants (after homogenization) were centrifuged at 10,000g for 15 min at 4°C to pellet mitochondrial SOD. The
supernatant contained cytosolic SOD. The standard curve for the SOD assay was generated using a quality-controlled SOD standard. Data
represent means  SD of three independent experiments. SOD enzyme activity was determined in duplicate. Signiﬁcance was calculated
using the Student’s t test (one-tailed, unpaired). Mitochondrial SOD: P < 0.0005 for LASY siRNA versus control siRNA; P < 0.005 for LASY
siRNALA100 versus LASY siRNA; P < 0.003 for LASYsiRNALA500 versus LASY siRNA. Cytosolic SOD: P < 0.0001 for LASY siRNA versus
control siRNA; P < 0.0007 for LASY siRNALA500 versus LASY siRNA. E: Effect of LASY knockdown on superoxide anion levels. Superoxide
anion levels were quantitated using a commercially available kit (Sigma-Aldrich), which measures the oxidation of luminol by superoxide
anions by chemiluminescence. Cells that were transfected with either control siRNA or LASY siRNA were treated with TNF- (1 ng/ml, 18 h)
24 h after transfection. The manufacturer’s protocol was followed for harvest of the cells and the assay. Luminescence intensity was
measured at various time points (5–20 min). Values at peak intensity are shown. Data represent means  SD of three independent
experiments. Assay was done in triplicate. Signiﬁcance was calculated using Student’s t test (one-tailed, unpaired). P < 0.003 for untreated
samples (control siRNA versus LASY siRNA); P < 0.03 for TNF-–treated samples (control siRNA versus LASY siRNA); P < 0.004 for control
siRNATNF versus control siRNATNFlipoic acid; P < 0.002 for LASY siRNATNF versus LASYsiRNATNFlipoic acid; P < 0.03
for control siRNATNFlipoic acid versus LASYsiRNATNFlipoic acid. , Control siRNA; , LASY siRNA.
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604 DIABETES, VOL. 58, MARCH 2009the levels of MCP-1 (Fig. 6B, P  0.02). These data
demonstrate an inverse relationship between LASY ex-
pression levels and secretion of MCP-1, suggesting that
inhibition of LASY expression increases inﬂammation.
Inhibition of LASY expression increases nuclear
translocation of nuclear factor-B. Nuclear factor
(NF)-B is a key transcription factor that is involved in the
transcription of over 150 known genes, including genes
encoding inﬂammatory markers such as MCP-1. Translo-
cation of NF-B into the nucleus is a key event in the
activation of NF-B. We investigated if inhibition of LASY
has an effect on TNF-–induced nuclear translocation of
the p65 subunit of NF-B. Western blot analysis of nuclear
extracts showed that siRNA-based knockdown of LASY
increased nuclear translocation of the NF-B p65 subunit
compared with the control after8ho ftreatment with TNF
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FIG. 5. Effect of LASY knockdown on glucose uptake and mitochondrial
membrane potential. A: Effect of siRNA-based knockdown of LASY
gene expression on insulin-stimulated glucose uptake in HSMMs.
Knockdown of LASY was done as described in RESEARCH DESIGN AND
METHODS. Cells were washed with DMEM containing 1% BSA and
incubated in this medium for 18 h. Cells were washed with transport
medium (20 mmol/l HEPES, pH 7.4, 140 mol/l NaCl, 5 mmol/l MgCl2,1
mmol/l CaCl2, and 0.1% (wt/vol) BSA. Next, cells were incubated in
transport medium with or without insulin (1 mol/l) for 30 min at
37°C/CO2. This was followed by incubation in transport buffer contain-
ing 10 mol/l 2-deoxy-D-[2,6-
3H]glucose (1.0 Ci/ml) for 30 min at 37°C.
Reactions were stopped by aspirating the media and washing cells with
PBS containing 20 mmol/l D-glucose at 4°C. Cells were lysed in 0.5%
(wt/vol) SDS, and radioactivity was measured by liquid scintillation
counting. Data were expressed per milligram of protein, determined by
using the bicinchoninic acid (BCA) method (Pierce Chemical Com-
pany). Glucose uptake values under basal (unstimulated) and insulin-
stimulated conditions are expressed as picomoles per minute per
milligram protein. Cells were stimulated with 1 mol/l insulin for 30
min in transport buffer, as described by Maddux et al. (9). Data
represent means  SE of three independent experiments. P values
were calculated using Student’s t test (one-tailed, unpaired). *P < 0.01
for LASY siRNA versus control siRNA for insulin-treated cells. Differ-
ence between LASY siRNA and control siRNA for basal unstimulated
cells is not signiﬁcant. B: Effect of siRNA-based LASY knockdown on
mitochondrial membrane potential in HSMMs. Knockdown was done as
described in the text. Mitochondrial membrane potential was deter-
mined using the JC-1 assay. After knockdown, cells were washed with
1 PBS and incubated with JC-1 dye as described in the JC-1 assay kit
(Biotium) for 30 min at 37°C. Cells were washed twice with 1 PBS,
trypsinized, and transferred to 96-well PCR tube plates. Red and green
ﬂuorescence was measured using the Envision ﬂuorescent plate reader
(Perkin Elmer). Results are expressed as ratio of red to green ﬂuores-
cence of JC-1. Data represent means  SD of three independent
experiments. P values were calculated using the Student’s t test
(one-tailed, unpaired). *P < 0.005 for LASY siRNA versus control
siRNA.
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FIG. 6. Effect of knockdown of the LASY gene on inﬂammation in
HMVECs. A: LASY mRNA levels in HMVECs treated with a LASY
siRNA oligo or control (scrambled) siRNA oligo; knockdown was
done for 48 h. Ct values from real-time PCR assay for LASY was
corrected for Ct values from Actin. Fold change in LASY expression
is shown relative to control; *P < 0.001 for LASY siRNA versus
control siRNA. B: MCP-1 levels in control siRNA and LASY siRNA-
treated cells under basal and TNF-–treated conditions. TNF-
(0.05 ng/ml) treatment was done in 1% serum medium after 24 h of
siRNA transfection. Duration of treatment with TNF- was 18 h.
Treatment supernatants were used in an ELISA to determine MCP-1
levels expressed as picograms per millilter. Data represent means 
SD of three independent experiments. P values were calculated
using Student’s t test (one-tailed, unpaired). *P < 0.05 for LASY
siRNA versus control siRNA (basal). **P < 0.02 for LASY siRNA
versus control siRNA (TNF-–treated). C: Western blot analysis of
NF-B p65 subunit levels in nuclear extracts from cells treated with
either control (scrambled) siRNA or LASY siRNA. Nuclear extracts
were prepared from cells that were treated with TNF- (0.05 ng/ml)
for 8 or 18 h. Treatments were done as described in the previous
section. A commercially available kit (Panomics) was used for the
nuclear extracts. Protein concentrations were determined by mi-
croBCA method as described previously. Nuclear extracts were
analyzed by Western blotting using polyclonal anti–NF-B p65 sub-
unit antibodies diluted 1:200 (Santa Cruz Biotechnology) to monitor
NF-B translocation. Results represent means  SE of three inde-
pendent experiments. P values were calculated using Student’s t
test (one-tailed, unpaired). *P < 0.002 for LASY siRNA versus
control siRNA for the 8-h time point.
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decreased after 18 h of TNF treatment, with no signiﬁcant
differences between control and LASY at this time point
(Fig. 6C).
Overexpression of LASY alleviates the inﬂammatory
response. We next studied the effect of overexpressing
LASY in endothelial cells, to conﬁrm that LASY does
indeed protect cells against inﬂammatory insults. The
LASY gene was cloned into pBK-CMV, so that its expres-
sion was under the control of the strong cytomegalovirus
(CMV) promoter. The resulting construct (pBKCMV-LASY)
was transfected into HMVECs, and the transfected cells
were treated with proinﬂammatory agents such as TNF-
or AGE. LASY mRNA levels were increased approximately
threefold in cells transfected with pBKCMV-LASY com-
pared with mock (pBKCMV)-transfected cells (Fig. 7A).
Cells that overexpressed LASY showed a signiﬁcant de-
crease in TNF-–stimulated secretion of MCP-1 compared
with mock-transfected cells (Fig. 7B, P  0.01). AGEs
generated by hyperglycemia are implicated in the devel-
opment of inﬂammation and atherosclerosis (10). We
looked at the effect of AGE treatment on MCP-1 levels in
cells that overexpressed LASY. As seen with TNF- treat-
ment, LASY overexpression caused a signiﬁcant decrease
in AGE-induced secretion of MCP-1 (Fig. 7B, P  0.005).
These results suggest that increased expression of LASY
alleviates inﬂammation.
Treatment with -lipoic acid increases LASY expres-
sion and has beneﬁcial effects on inﬂammation and
mitochondrial membrane potential. Real-time PCR
studies revealed that treatment of cells with lipoic acid
(500 mol/l) upregulates LASY expression by 3.5-fold
(Fig. 8A, P  0.003). Lower concentrations of lipoic acid
(100 mol/l) did not increase LASY expression. The effects
of lipoic acid on LASY gene expression correlates with its
anti-inﬂammatory effect in TNF-–induced inﬂammation
(Fig. 8B, P  0.005) and its beneﬁcial effects on mitochon-
drial membrane potential (Fig. 8C, P  0.0001).
DISCUSSION
Our studies demonstrate for the ﬁrst time that LASY, a
mitochondrial enzyme responsible for synthesis of lipoic
acid, a potent antioxidant, is downregulated in animal
models of type 2 diabetes and obesity. Downregulation of
LASY in leptin/leptin receptor–deﬁcient models could be a
secondary effect of hyperglycemia and increased cytokine
expression in these models. Our in vitro data demonstrate
that treatment of endothelial and skeletal muscle cells
with high glucose and TNF- decreases LASY expression.
Data from our in vitro gene silencing studies reveal that
knockdown of LASY has detrimental effects on various
aspects of cellular function. One of them is the disruption
of the antioxidant defense system. We have shown that
knockdown of LASY results in a signiﬁcant decrease in the
activities of two critical antioxidant enzymes, SOD and
CAT, which are involved in maintaining intracellular redox
balance. Deﬁciency of LASY reduced activities of both
mitochondrial and cytosolic SOD. The net effect of reduc-
tion in SOD and CAT activities would be increased accu-
mulation of reactive species such as superoxide anion, a
highly reactive species that would have been normally
detoxiﬁed by SOD and CAT in a sequential manner to H2O2
and water. This hypothesis turned out to be true, since
there was a signiﬁcant increase in the intracellular super-
oxide anions under basal and TNF-–treated conditions
after LASY knockdown. Thus, downregulation of LASY
results in an overall disturbance in the antioxidant defense
network, tipping the balance toward oxidative stress.
Treatment with exogenous lipoic acid restored the activi-
ties of SOD and catalase but was unable to reduce the
superoxide anion levels. In our experiment, we saw a
signiﬁcant increase in superoxide anion levels with lipoic
acid treatment in both the control and LASY siRNA-treated
samples in response to TNF- treatment. This may be due
to the pro-oxidant activity of lipoic acid that has been
reported in the literature (11). Disturbance in the endoge-
nous antioxidant network is reﬂected in decreased GSH
levels, suggesting inability to regenerate reduced glutathi-
one. Our in vitro data showing that knockdown of LASY
results in decreased GSH levels is consistent with pub-
lished literature. A signiﬁcant decrease in erythrocyte GSH
levels has been reported in mice that are heterozygous for
disruption of the LASY gene (12).
Accumulation of excessive amounts of ROS such as
superoxide anion could directly inﬂict damage on cellular
macromolecules. Because mitochondria are a major site of
ROS generation, accumulated ROS could cause damage to
the mitochondrial membrane, resulting in its inability to
maintain a gradient. This could then lead to mitochondrial
dysfunction. The decrease in mitochondrial membrane
potential that we have demonstrated in our in vitro LASY
knockdown studies could be a result of damage caused by
ROS. In addition, accumulated ROS can activate inﬂam-
matory pathways such as the NF-B pathway, which can
lead to increased expression of inﬂammatory cytokines.
We found that LASY knockdown in endothelial cells
increases TNF-–induced NF-B translocation into the
nucleus. Our data suggest that knockdown of LASY and
the consequent accumulation of ROS triggers the activa-
tion of NF-B, resulting in increased expression of NF-B–
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FIG. 7. Overexpression of LASY in HMVECs and effect of proinﬂam-
matory agents on MCP-1 expression in HMVECs overexpressing the
LASY gene. A: LASY mRNA levels in cells transfected with either the
mock plasmid (pBKCMV) or pBKCMV-LASY. Transfections were
done for 48 h. LASY expression was monitored by real-time PCR.
Fold changes are expressed relative to Mock (pBKCMV)-treated
control. Ct values obtained from LASY primers were corrected for
Ct values from Actin primers. B: MCP-1 levels in supernatants from
cells transfected with either mock (pBKCMV) or pBKCMV-LASY
plasmid. Treatments with TNF- and AGE were done for 18 h in 1%
serum medium. Concentrations used were as follows: TNF-: 0.05
ng/ml; AGE: 300 g/ml. MCP-1 levels were determined by ELISA and
expressed as pg/ml. Data represent means  SD of three indepen-
dent experiments. P values were calculated using the Student’s t
test (one-tailed, unpaired). *P < 0.01 for TNF-–treated cells and
**P < 0.005 for AGE-treated cells, respectively (LASY versus Mock).
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circulating inﬂammatory cytokines and mitochondrial dys-
function contribute to insulin resistance, which could
account for the decrease in glucose uptake in skeletal
muscle after knockdown of LASY. It has been suggested
that accumulation of ROS could be interpreted by the cell
as an imbalance between substrate availability and oxida-
tive capacity to which decreased insulin signaling (and
thus decreased glucose uptake) would be an appropriate
response (13). Decreased insulin signaling due to ROS has
been attributed to decreased levels of phosphorylated Akt
accompanied by an increase in phosphorylated JNK
(13,14).
Increased secretion of inﬂammatory cytokines, mito-
chondrial dysfunction, and decreased glucose uptake after
LASY knockdown could all contribute to further deterio-
ration of hyperglycemia and associated metabolic abnor-
malities in animal models of diabetes and obesity. In db/db,
fa/fa, and ob/ob models, which are already deﬁcient in
leptin signaling, deﬁciency in LASY would therefore accel-
erate progression of disease.
Downregulation of LASY is not a phenomenon restricted
to animal models of diabetes. We studied blood samples
from human subjects with type 2 diabetes for LASY
expression by real-time PCR. These studies revealed sig-
niﬁcant downregulation of the LASY gene in subjects with
diabetes compared with age- and sex-matched healthy
individuals (data not shown).
Our studies demonstrate that deﬁciency of LASY results
in a decrease in mitochondrial lipoic acid levels. Using
antibodies that recognize protein-bound lipoic acid, we
have shown that knockdown of LASY reduces lipoic acid
associated with two key enzyme complexes, namely PDC
and KDH. Thus, deﬁciency of LASY directly affects levels
of lipoic acid within the mitochondria. The correlation
between LASY expression and mitochondrial lipoic acid is
also evident in the adipose tissue of db/db mice, where
deﬁciency of LASY results in a decrease in levels of lipoic
acid (Fig. 1C).
Reduced mitochondrial lipoic acid levels due to LASY
deﬁciency could be the predominant cause of the distur-
bances in the antioxidant defense system manifested as
reduced SOD and CAT activities, increased superoxide
anion levels, and decreased intracellular GSH. Because
endogenous lipoic acid is a potent antioxidant, it is con-
ceivable that a decrease in endogenous lipoic acid could
cause perturbations in the endogenous antioxidant sys-
tem. Supplementation with exogenous lipoic acid was able
to completely restore SOD and CAT activities in a dose-
dependent manner. This suggests that exogenously admin-
istered lipoic acid can compensate for the deﬁciency of
LASY. Interestingly, our data show that exogenously ad-
ministered lipoic acid increases the expression of LASY (at
500 mol/l), suggesting that exogenously administered
lipoic acid promotes its own generation. Thus, some of the
known beneﬁcial effects of lipoic acid administration
could be attributed to an indirect effect of endogenous
lipoic acid generation by increasing LASY levels.
Although lipoic acid is a critical cofactor of PDC,
knockdown of LASY did not appear to have an immediate
effect on the phosphorylation state of PDC, which is
inversely related to its activity (15) (Supplementary Fig. 3).
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FIG. 8. Improvement in mitochondrial function and decrease in inﬂammation by exogenous lipoic acid correlates with LASY induction. A: LASY
gene expression in HSMMs after treatment with 100 and 500 mol/l of LA. ()-–Lipoic acid was used in this experiment. Fold change is
expressed as percent of untreated cells. Data represent means  SD of three independent experiments. *P < 0.003 for LA500-treated cells versus
untreated. B: Expression of MCP-1 in HSMMs treated with 100 or 500 mol/l of lipoic acid in response to TNF (1 ng/ml) treatment. Cells were
treated with 0, 100, or 500 mol/l of lipoic acid for 1 h before addition of 1 ng/ml of TNF-. Cell treatments were allowed to proceed for 18 h.
MCP-1 expression was determined by real-time PCR. Fold change is shown relative to untreated cells. Data represent means  SD of three
independent experiments. *P < 0.005 for TNFLA500-treated cells versus TNF-treated cells. C: Mitochondrial membrane potential in HSMMs
treated with 100 and 500 mol/l lipoic acid was determined using the JC-1 assay. Results are expressed as the ratio of red to green ﬂuorescence
of JC-1. Data are the average of three independent experiments. P values were calculated using Student’s t test (one-tailed, unpaired). *P <
0.0001 (C) for LA500-treated cells versus untreated cells.
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agreement with the data from in vivo LASY knockdown
studies in which PDC activity was reported to be normal in
the livers from Lias
/ mice (12). Conceivably, because of
the critical function of PDC in glucose metabolism, there
are compensatory mechanisms that ensure that PDC ac-
tivity is not affected by lipoic acid deﬁciency. However, it
is possible that deﬁciency of lipoic acid may affect other
enzymes/pathways that we have not included in this study.
In conclusion, our data identify a novel role for LASY in
inﬂammation, insulin resistance, and mitochondrial dys-
function. Our data demonstrate that LASY plays a critical
role in the maintenance of the endogenous antioxidant
defense network, deﬁciency of which can aggravate the
metabolic abnormalities associated with type 2 diabetes.
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